Eastman Kodak's Quiet Turnaround: Net Cash, Film Resurgence, and a Third Consecutive Quarter of Growth

The bankrupt former film giant is now a stable, debt-free specialty materials company — but the market is yet to be convinced.

KODK · Earnings Call · 2026-05-07

Consistency, Stability, and Growth

The first quarter of 2026 marked a notable inflection point for Eastman Kodak Company. “The story of the first quarter is a story of consistency, stability, and growth.” — James V. Continenza, Chief Executive Officer · 2026-05-07 This isn't mere rhetoric — the numbers back it up. Consolidated revenue rose 7% year-over-year to $265 million, gross profit jumped 24% to $57 million, and Operational EBITDA surged to $15 million from a paltry $2 million in the prior-year quarter. As CFO David Bullwinkle noted, “This is the third consecutive quarter of year-over-year growth for these measures.” — David Edward Bullwinkle, Chief Financial Officer · 2026-05-07 For a company that has spent the better part of a decade shrinking, this is a narrative shift worth watching.

Balance Sheet as a Strategic Weapon

The most dramatic change lies not in the income statement but on the balance sheet. Kodak ended the quarter with $299 million in unrestricted cash and, for the second consecutive quarter, a positive position in net debt — meaning cash exceeds debt. This is the culmination of years of deleveraging, turbocharged by the termination of the CREP pension plan in 2025. The plan termination released significant cash, enabling a $50 million principal payment on higher-rate term loans in March. But it also created a $4 million non-cash pension income headwind, which the CFO warned will recur each quarter this year. Indeed, pension income has been the company's top keyword in the latest quarter, underscoring how central this one-time event is to the current financial picture. The company's Effective Net Cash now stands at $198 million, up from -$317 million a year ago. This is a structural change that gives management the flexibility to invest in growth without the overhang of debt service.

I am proud to say today, we are net debt positive.
James V. Continenza, Chief Executive Officer · 2026-05-07

That pride is well-founded, but it also sets a higher bar for capital allocation — investors will be watching whether the company can deploy this cash effectively rather than simply hoarding it.

Investing in the Core: Film and Pharma

Kodak is not just shrinking its way to stability; it is actively reinvesting in its most promising franchises. The Film business is a clear focus. Management highlighted the launch of a professional still film sold directly to distributors, and the growing use of Kodak motion picture film in prestige productions — from 'One Battle After Another' to Christopher Nolan's 'The Odyssey.' The company's CGMP pharmaceutical manufacturing facility is now running, and a new Advanced Electrophysiology Lab in partnership with SUNY Geneseo signals intent to move up the value chain. At the same time, the commercial print segment grew 9% despite "difficult times" — including aluminum supply disruptions and soaring raw material costs. The launch of the Sonora Ultra XR Plate in Europe is a tangible sign that product innovation continues. However, these investments are not without friction. The company took a $12 million charge on the fair value of an embedded derivative related to Series B preferred stock — a direct consequence of the rising share price. While non-cash, it swung the quarter to a GAAP net loss of $16 million. The stock itself has given back ground, falling 32% from its May 6 peak of $14.51 as the initial optimism faded and the market weighed the modest scale of improvement.

Why It Matters

The significance of Kodak's quarter is not the absolute numbers — $265 million in revenue is a far cry from its $15 billion peak — but the direction. Three consecutive quarters of growth, a fortress balance sheet, and a credible roadmap in film and pharma suggest that the company has finally found its footing. That said, the market's lukewarm reaction underscores the doubts. With a market cap under $1 billion and a trailing price-to-revenue multiple of 0.8x, the stock is priced for stagnation, not transformation. Kodak's challenge now is to prove it can sustain this momentum and convert its operational EBITDA into meaningful free cash flow. The ingredients are in place; execution is the next test.